SCHEMBL202856

SCHEMBL202856

CCCc1ccc(-c2ccccc2C(=O)N2CC[C@H](N)[C@H]2C(=O)NO)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 4/20 0.38
HCRTR2 O43614 4/20 0.38
KDM1A O60341 1/20 0.37
MLNR O43193 2/20 0.37
CYP3A4 P08684 2/20 0.37
MMP8 P22894 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37
PPARG P37231 2/20 0.37
LMNA P02545 1/20 0.36
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
MCOLN3 Q8TDD5 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
MTTP P55157 1/20 0.35
KDM2B Q8NHM5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201399 0.92 HCRTR1 (0.39) HCRTR1HCRTR2KDM1AMLNRCYP3A4
SCHEMBL201878 0.89 HCRTR1 (0.38) HCRTR1HCRTR2MLNRCYP3A4MMP8
SCHEMBL200952 0.88 HCRTR1 (0.40) HCRTR1HCRTR2KDM1AMLNRCYP3A4
SCHEMBL201008 0.88 HCRTR1 (0.38) HCRTR1HCRTR2MLNRCYP3A4MMP8
SCHEMBL202594 0.87 HCRTR1 (0.39) HCRTR1HCRTR2MLNRCYP3A4MMP8
SCHEMBL201630 0.86 LMNA (0.38) HCRTR1HCRTR2MLNRCYP3A4MMP8
SCHEMBL203250 0.86 LMNA (0.38) HCRTR1HCRTR2MLNRCYP3A4MMP8
SCHEMBL203379 0.85 MMP13 (0.38) KDM1AMLNRCYP3A4MMP8MMP13
SCHEMBL201676 0.85 MMP13 (0.38) KDM1AMLNRCYP3A4MMP8MMP13
SCHEMBL200879 0.85 HCRTR1 (0.38) HCRTR1HCRTR2MLNRCYP3A4MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 HCRTR1 1201/4885HCRTR2 1892/4885KDM1A 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.